Pictet Asset Management Holding SA Invests $20.60 Million in Janux Therapeutics, Inc. (NASDAQ:JANX)

Pictet Asset Management Holding SA acquired a new stake in shares of Janux Therapeutics, Inc. (NASDAQ:JANX - Free Report) during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 384,797 shares of the company's stock, valued at approximately $20,602,000. Pictet Asset Management Holding SA owned approximately 0.73% of Janux Therapeutics at the end of the most recent quarter.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Avanza Fonder AB bought a new position in shares of Janux Therapeutics during the fourth quarter valued at about $139,000. Chicago Capital LLC purchased a new position in Janux Therapeutics in the 4th quarter worth approximately $230,000. Y Intercept Hong Kong Ltd bought a new stake in Janux Therapeutics during the 3rd quarter valued at $317,000. Virtu Financial LLC boosted its position in Janux Therapeutics by 48.0% during the 3rd quarter. Virtu Financial LLC now owns 7,463 shares of the company's stock valued at $339,000 after buying an additional 2,419 shares during the period. Finally, Legato Capital Management LLC bought a new stake in Janux Therapeutics in the 4th quarter worth $347,000. Hedge funds and other institutional investors own 75.39% of the company's stock.

Insider Activity at Janux Therapeutics

In other Janux Therapeutics news, insider Andrew Hollman Meyer sold 3,334 shares of Janux Therapeutics stock in a transaction dated Monday, February 3rd. The shares were sold at an average price of $42.29, for a total value of $140,994.86. Following the completion of the transaction, the insider now directly owns 82,139 shares of the company's stock, valued at approximately $3,473,658.31. The trade was a 3.90 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Ra Capital Management, L.P. bought 341,742 shares of the business's stock in a transaction on Wednesday, March 5th. The shares were acquired at an average price of $30.64 per share, for a total transaction of $10,470,974.88. Following the completion of the purchase, the director now owns 9,658,988 shares in the company, valued at approximately $295,951,392.32. The trade was a 3.67 % increase in their position. The disclosure for this purchase can be found here. Insiders sold a total of 11,668 shares of company stock valued at $548,183 in the last 90 days. Corporate insiders own 29.40% of the company's stock.

Remove Ads

Wall Street Analysts Forecast Growth

JANX has been the topic of several recent analyst reports. Scotiabank cut their target price on Janux Therapeutics from $62.00 to $41.00 and set a "sector perform" rating on the stock in a research note on Friday, February 28th. HC Wainwright reiterated a "buy" rating and issued a $70.00 price objective on shares of Janux Therapeutics in a research report on Monday, March 3rd. Lifesci Capital upgraded Janux Therapeutics to a "strong-buy" rating in a report on Friday, December 27th. Wedbush reiterated an "outperform" rating and issued a $76.00 price target (up previously from $75.00) on shares of Janux Therapeutics in a report on Friday, February 28th. Finally, William Blair reissued an "outperform" rating on shares of Janux Therapeutics in a research report on Friday, January 10th. One research analyst has rated the stock with a hold rating, nine have assigned a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Buy" and a consensus price target of $92.44.

Janux Therapeutics Stock Performance

Shares of Janux Therapeutics stock traded down $1.22 during trading on Friday, hitting $25.77. The company's stock had a trading volume of 831,224 shares, compared to its average volume of 852,552. Janux Therapeutics, Inc. has a 52 week low of $24.30 and a 52 week high of $71.71. The company has a market capitalization of $1.52 billion, a PE ratio of -22.03 and a beta of 3.27. The company has a fifty day simple moving average of $34.09 and a two-hundred day simple moving average of $45.26.

Janux Therapeutics (NASDAQ:JANX - Get Free Report) last announced its earnings results on Thursday, February 27th. The company reported ($0.36) earnings per share for the quarter, beating analysts' consensus estimates of ($0.49) by $0.13. Janux Therapeutics had a negative net margin of 463.91% and a negative return on equity of 10.47%. As a group, analysts predict that Janux Therapeutics, Inc. will post -1.38 EPS for the current year.

About Janux Therapeutics

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.